Difference between revisions of "Liposarcoma"

Jump to navigation Jump to search
7 bytes added ,  14:12, 11 April 2022
no edit summary
(D-dimer)
 
Line 39: Line 39:
**Extremity: good - disease specific 5-year survival ~ 92%.<ref>{{Cite journal  | last1 = Lietman | first1 = SA. | last2 = Barsoum | first2 = WK. | last3 = Goldblum | first3 = JR. | last4 = Marks | first4 = KE. | last5 = Mascha | first5 = E. | last6 = Sundaram | first6 = M. | last7 = Muschler | first7 = G. | title = A 20-year retrospective review of surgically treated liposarcoma at the Cleveland Clinic. | journal = Orthopedics | volume = 30 | issue = 3 | pages = 227-34 | month = Mar | year = 2007 | doi =  | PMID = 17375550 }}</ref>  
**Extremity: good - disease specific 5-year survival ~ 92%.<ref>{{Cite journal  | last1 = Lietman | first1 = SA. | last2 = Barsoum | first2 = WK. | last3 = Goldblum | first3 = JR. | last4 = Marks | first4 = KE. | last5 = Mascha | first5 = E. | last6 = Sundaram | first6 = M. | last7 = Muschler | first7 = G. | title = A 20-year retrospective review of surgically treated liposarcoma at the Cleveland Clinic. | journal = Orthopedics | volume = 30 | issue = 3 | pages = 227-34 | month = Mar | year = 2007 | doi =  | PMID = 17375550 }}</ref>  
**D-dimer (serum) useful; elevated levels in keeping with liposarcoma.
**D-dimer (serum) useful; elevated levels in keeping with liposarcoma.
***Cut point 0.41 μg/ml for metastasis: sensitivity 0.83 and specificity 0.57.<ref name=pmid22044610>{{cite journal |authors=Morii T, Mochizuki K, Tajima T, Ichimura S, Satomi K |title=D-dimer levels as a prognostic factor for determining oncological outcomes in musculoskeletal sarcoma |journal=BMC Musculoskelet Disord |volume=12 |issue= |pages=250 |date=November 2011 |pmid=22044610 |pmc=3226444 |doi=10.1186/1471-2474-12-250 |url=}}</ref>
***Cut-off value 0.41 μg/ml for metastasis: sensitivity 0.83 and specificity 0.57.<ref name=pmid22044610>{{cite journal |authors=Morii T, Mochizuki K, Tajima T, Ichimura S, Satomi K |title=D-dimer levels as a prognostic factor for determining oncological outcomes in musculoskeletal sarcoma |journal=BMC Musculoskelet Disord |volume=12 |issue= |pages=250 |date=November 2011 |pmid=22044610 |pmc=3226444 |doi=10.1186/1471-2474-12-250 |url=}}</ref>
***Cut point 0.80 μg/ml for total survival: sensitivity 0.80 and specificity 0.75.<ref name=pmid22044610/>
***Cut-off value 0.80 μg/ml for total survival: sensitivity 0.80 and specificity 0.75.<ref name=pmid22044610/>


Notes:
Notes:
*Retroperitoneal sarcomas: #1: liposarcoma, #2: [[pleomorphic undifferentiated sarcoma]], #3: [[leiomyosarcoma]], #4: [[MPNST]].
*Retroperitoneal sarcomas: #1: liposarcoma, #2: [[pleomorphic undifferentiated sarcoma]], #3: [[leiomyosarcoma]], #4: [[MPNST]].
**Extremely rare in retroperitoneum: [[synovial sarcoma]].
**Extremely rare in retroperitoneum: [[synovial sarcoma]].


==Gross==
==Gross==
48,453

edits

Navigation menu